REGPAL PHARMA CONSULTING PRIVATE LIMITED
REGPAL PHARMA CONSULTING PRIVATE LIMITED is a MAHARASHTRA based PRIVATE LIMITED company, Registered at dated 25-OCT-2021 on Ministry of Corporate Affairs(MCA), The Corporate Identification Number (CIN) of REGPAL PHARMA CONSULTING PRIVATE LIMITED is U74999MH2021PTC370136 and registration number is 370136.
It has been classified as COMPANY LIMITED BY SHARES and is registered under Registar of Companies MUMBAI India. Authorized share capital of REGPAL PHARMA CONSULTING PRIVATE LIMITED is Rs. 100000 and its paid up capital is Rs. 100000. It aspire to serve in OTHER BUSINESS ACTIVITIES activities across the India.
Its Annual General Meeting (AGM) was lastly conducted on and as per the records of Ministry of Corporate Affairs (MCA), its balance sheet was last filed on .
REGPAL PHARMA CONSULTING PRIVATE LIMITED has 2 directors SHWETA DATTATRAY TUPE PATIL, PALLAVI SUHAS KATARE,
The registered Email address of REGPAL PHARMA CONSULTING PRIVATE LIMITED is regulatorypalservices@gmail.com and its registered address is H9/1 1 SECT 8 NEWPANVEL RAIGARH MH 410218 IN MAHARASHTRA MAHARASHTRA india 410218.
The current status of REGPAL PHARMA CONSULTING PRIVATE LIMITED shows as ACTIVE
COMPANY BASIC DETAILS
REGPAL PHARMA CONSULTING PRIVATE LIMITED
MUMBAI
ACTIVE
OTHER BUSINESS ACTIVITIES
U74999MH2021PTC370136
25-OCT-2021
COMPANY LIMITED BY SHARES
NON-GOVT COMPANY
PRIVATE
100000
100000
CONTACT DETAILS
410218
INDIA
H9/1 1 SECT 8 NEWPANVEL RAIGARH MH 410218 IN
regulatorypalservices@gmail.com
DIRECTOR DETAILS
DIN | Director Name | Designation | Appointment Date |
---|---|---|---|
09373515 | SHWETA DATTATRAY TUPE PATIL | Director | 25/10/2021 |
09373516 | PALLAVI SUHAS KATARE | Director | 25/10/2021 |
Details Updated by Companies
Quick Links
- All Registered company of MAHARASHTRA
- Company Registered in MAHARASHTRA
- All Registered company of RAIGARH(MH) in MAHARASHTRA
- Listed Company
- Company Category
- Latest Registered Company
Contact Us for Update Extra Information about your company and services.